The title compound N-(2-(2-hydroxy-2-phenylacetyl)phenyl)cinnamamide(C23H19NO3,Mr=357.39)has been synthesized with 2-iodoaniline and ethynylbenzene as starting materials,and its crystal structure was determined by ^1H...The title compound N-(2-(2-hydroxy-2-phenylacetyl)phenyl)cinnamamide(C23H19NO3,Mr=357.39)has been synthesized with 2-iodoaniline and ethynylbenzene as starting materials,and its crystal structure was determined by ^1H NMR,^13C NMR,H RMS and single-crystal X-ray diffraction for the first time.The crystal crystallizes in monoclinic system,space group P21/c with a=8.2850(7),b=25.934(2),c=8.3032(6)A,β=95.314(7)°,V=1776.4(3)A^3,Z=4,T=293(2)K,μ(Cu Kα)=0.71 mm^-1,Dc=1.336 Mg/cm3,3019 reflections measured(6.832≤2θ≤129.982°),2996 unique(Rint=0.0463,Rsigma=0.0549)which were used in all calculations.The final R=0.0880(I>2σ(I))and wR=0.2447(all data).The target compound has demonstrated weak or moderate anti-tumor activity against human leukemia k562 cell,human promyelocytic leukemia HL-60 cell,human gastric cancer line BGC-823,Hela cell and lung cancer A549 cell.展开更多
基金supported by the construct program of applied characteristic discipline in Hunan University of Science and Engineering,Research Learning and Innovative Experimental Program for College Students of Hunan University of Science and Engineering(No.[2018]32-51)the opening project of key laboratory of comprehensive utilization of advantage plants resources in Hunan south,Hunan university of science and engineering(No.XNZW17C04,XNZW17C05)the Planned Science and Technology Project of Hunan Yongzhou,China(No.2018ZD15)
文摘The title compound N-(2-(2-hydroxy-2-phenylacetyl)phenyl)cinnamamide(C23H19NO3,Mr=357.39)has been synthesized with 2-iodoaniline and ethynylbenzene as starting materials,and its crystal structure was determined by ^1H NMR,^13C NMR,H RMS and single-crystal X-ray diffraction for the first time.The crystal crystallizes in monoclinic system,space group P21/c with a=8.2850(7),b=25.934(2),c=8.3032(6)A,β=95.314(7)°,V=1776.4(3)A^3,Z=4,T=293(2)K,μ(Cu Kα)=0.71 mm^-1,Dc=1.336 Mg/cm3,3019 reflections measured(6.832≤2θ≤129.982°),2996 unique(Rint=0.0463,Rsigma=0.0549)which were used in all calculations.The final R=0.0880(I>2σ(I))and wR=0.2447(all data).The target compound has demonstrated weak or moderate anti-tumor activity against human leukemia k562 cell,human promyelocytic leukemia HL-60 cell,human gastric cancer line BGC-823,Hela cell and lung cancer A549 cell.